View in EDS HTML Full Text PDF Full Text

Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma.

Saved in:
Bibliographic Details
Title: Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma.
Authors: Lutz R; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany., Poos AM; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.; Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg University and German Cancer Research Center (DKFZ), Heidelberg, Germany., Solé-Boldo L; Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, Berlin, Germany.; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin, Germany.; Precision Healthcare University Research Institute, Queen Mary University of London, London, UK., John L; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.; Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg University and German Cancer Research Center (DKFZ), Heidelberg, Germany., Wagner J; Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany., Prokoph N; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.; Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg University and German Cancer Research Center (DKFZ), Heidelberg, Germany., Baertsch MA; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.; Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg University and German Cancer Research Center (DKFZ), Heidelberg, Germany., Vonficht D; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany., Palit S; Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, Berlin, Germany.; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin, Germany., Brobeil A; Department of Pathology, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.; Tissue Bank of the National Center for Tumor Diseases (NCT) Heidelberg, Heidelberg, Germany., Mechtersheimer G; Department of Pathology, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany., Hildenbrand N; Department of Orthopaedics, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany., Hemmer S; Department of Orthopaedics, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany., Steiger S; Division of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany., Horn S; Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, Berlin, Germany.; Institute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany., Pepke W; Department of Orthopaedics, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany., Spranz DM; Department of Orthopaedics, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany., Rehnitz C; Department of Radiology, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany., Sant P; Single Cell Open Lab, German Cancer Research Center (DKFZ), Heidelberg, Germany., Mallm JP; Single Cell Open Lab, German Cancer Research Center (DKFZ), Heidelberg, Germany., Friedrich MJ; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany., Reichert P; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany., Huhn S; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany., Trumpp A; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), Heidelberg, Germany.; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany., Rippe K; Division of Chromatin Networks, German Cancer Research Center (DKFZ) and BioQuant, Heidelberg, Germany., Haghverdi L; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany., Fröhling S; Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; Institute of Human Genetics, Heidelberg University, Heidelberg, Germany., Müller-Tidow C; National Center for Tumor Diseases (NCT), NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, Heidelberg, Germany.; Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany., Hübschmann D; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM), Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany.; Computational Oncology, Molecular Precision Oncology Program, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany., Goldschmidt H; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.; GMMG-Study Group at Heidelberg University Hospital, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany., Willimsky G; Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, Berlin, Germany.; Institute of Immunology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), partner site Berlin, Berlin, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Sauer S; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany., Raab MS; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.; Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg University and German Cancer Research Center (DKFZ), Heidelberg, Germany., Haas S; Berlin Institute of Health (BIH) at Charité Universitätsmedizin Berlin, Berlin, Germany.; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin, Germany.; Precision Healthcare University Research Institute, Queen Mary University of London, London, UK.; German Cancer Consortium (DKTK), partner site Berlin, Berlin, Germany., Weinhold N; Heidelberg Myeloma Center, Department of Internal Medicine V, Heidelberg University Hospital, Medical Faculty, Heidelberg University, Heidelberg, Germany.; Clinical Cooperation Unit Molecular Hematology/Oncology, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg University and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Source: Science immunology [Sci Immunol] 2025 Feb 07; Vol. 10 (104), pp. eadp6667. Date of Electronic Publication: 2025 Feb 07.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101688624 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2470-9468 (Electronic) Linking ISSN: 24709468 NLM ISO Abbreviation: Sci Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2470-9468
DOI:10.1126/sciimmunol.adp6667